Document is current
Any future updates will be listed below
-
Authors
Smolen, Josef S https://orcid.org/0000-0002-4302-8877
Mikuls, Ted R
Galloway, James https://orcid.org/0000-0002-1230-2781
Müller-Ladner, Ulf
Curtis, Jeffrey R
Hashimoto, Motomu
Takeuchi, Tsutomu
Choy, Ernest https://orcid.org/0000-0003-4459-8609
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Cara, Carlos
Lauwerys, Bernard https://orcid.org/0000-0003-3243-6151
Tilt, Nicola
Ufuktepe, Baran
Taylor, Peter C https://orcid.org/0000-0001-7766-6167
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00717236 at ClinicalTrials.govnct00717236 at ClinicalTrials.govDocuments that mention this clinical trial
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial
https://doi.org/10.1136/rmdopen-2025-006094
AB0638 DO HIGH RHEUMATOID FACTOR LEVELS IMPACT RESPONSE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH INADEQUATELY CONTROLLED RHEUMATOID ARTHRITIS? A POST HOC ANALYSIS OF THE PHASE 3B REALISTIC TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.2883
Documents that mention this clinical trial
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial
https://doi.org/10.1136/rmdopen-2025-006094
AB0638 DO HIGH RHEUMATOID FACTOR LEVELS IMPACT RESPONSE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH INADEQUATELY CONTROLLED RHEUMATOID ARTHRITIS? A POST HOC ANALYSIS OF THE PHASE 3B REALISTIC TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.2883
-
Funding
Funding for this research was provided by:
UCB
- License Information
